Physician profile
Christopher Lopez
NPI 1922514447
$48,028.31
in general payments reported to CMS, 2019-2025
18 companies · $15K in 2025
The $15K reported for 2025 was more than what 99% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $350 · 2020: $57.86 · 2021: $11K · 2022: $5,157 · 2023: $5,348 · 2024: $11K · 2025: $15K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $14K · Consulting Fee: $11K · Travel and Lodging: $5,978 · Food and Beverage: $1,664.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $13,510.00 |
| Consulting Fee | $10,562.50 |
| Travel and Lodging | $5,978.46 |
| Food and Beverage | $1,664.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coopervision INC. | $28,193.97 | 2020-2025 | Misight Contact Lens, Myday Contact Lens |
| Alcon Vision LLC | $16,285.00 | 2019-2025 | Total30, Dailies Total1, Precision 1 |
| Bausch & Lomb Americas INC. | $2,536.23 | 2022 | |
| Tarsus Pharmaceuticals, INC. | $301.99 | 2024-2025 | Xdemvy |
| Genzyme Corporation | $117.68 | 2019 | |
| Abbvie INC. | $99.71 | 2022 | |
| Johnson & Johnson Vision Care, INC. | $76.32 | 2019-2025 | |
| Lkc Technologies, INC. | $71.92 | 2023 | |
| Harrow Eye, LLC | $70.00 | 2025 | Vevye |
| Oyster Point Pharma, INC. | $65.07 | 2023-2025 | Tyrvaya, Ryzumvi |
| Dompe US, INC. | $57.68 | 2025 | Oxervate |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $32.20 | 2019 | |
| Ani Pharmaceuticals, INC. | $31.70 | 2025 | Purified Cortrophin Gel |
| Ocular Therapeutix, INC. | $31.25 | 2024-2025 | Dextenza |
| Novartis Pharmaceuticals Corporation | $22.79 | 2023 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shire North American Group INC | $20.48 | 2019 | |
| Allergan, INC. | $14.32 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Lopez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.